Last 277.50 GBp
Change Today 0.00 / 0.00%
Volume 0.0
EHP On Other Exchanges
Symbol
Exchange
Berlin
As of 7:35 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

epistem holdings plc (EHP) Snapshot

Open
277.50 GBp
Previous Close
277.50 GBp
Day High
277.50 GBp
Day Low
277.50 GBp
52 Week High
06/18/14 - 340.00 GBp
52 Week Low
11/17/14 - 277.50 GBp
Market Cap
27.8M
Average Volume 10 Days
71.0K
EPS TTM
-0.17 GBp
Shares Outstanding
10.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EPISTEM HOLDINGS PLC (EHP)

Related News

No related news articles were found.

epistem holdings plc (EHP) Related Businessweek News

No Related Businessweek News Found

epistem holdings plc (EHP) Details

Epistem Holdings Plc, a biotechnology and personalised medicine company, provides pre-clinical testing, pharmacogenomic biomarker, and diagnostic testing services to the biotechnology and pharmaceutical industries in Europe, the United States, and Asia. It operates through three divisions: Preclinical Research Services, Personalised Medicine, and Novel Therapies. The Preclinical Research Services division provides preclinical efficacy testing, immunohistochemistry services, and cell biology expertise in the areas of oncology, oncology supportive care, inflammatory bowel disease, rheumatoid arthritis, and dermatology. The Personalised Medicine division offers sensitive molecular measures of biological processes that enhance precision in drug development and disease treatment. This division discovers, develops, and translates biomarkers for clinical drug development and companion diagnostics; and offers Genedrive, a molecular diagnostic device used in bacterial, viral, fungal, and somatic mutations disease identification. The Novel Therapies division discovers and develops regulators of epithelial stem cells and tissues. Epistem Holdings Plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.

Founded in 2000

epistem holdings plc (EHP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 302.0K GBP
Co-Founder, Managing Director of Contract Res...
Total Annual Compensation: 107.3K GBP
Chief Financial Officer, Finance Director, Co...
Total Annual Compensation: 133.1K GBP
Chief Operating Officer of Diagnostics and Di...
Total Annual Compensation: 62.5K GBP
Compensation as of Fiscal Year 2014.

epistem holdings plc (EHP) Key Developments

Epistem Holdings plc Appoints Ian Gilham as Non-Executive Director and Chairman

EpiStem Holdings Plc announced that Ian Gilham has joined the Board as a non-executive director and chairman designate with immediate effect. As previously announced, David Evans, the chairman of Epistem since 2006 will be standing down as chairman at the point that the company launches Genedrive® its revolutionary handheld molecular diagnostic device in India, which is expected early in 2015. an David Gilham, aged 54, is currently non-executive chairman of three life sciences companies including AIM quoted Horizon Discovery Group plc, which provides research tools to support translational genomics and the development of personalised medicine, Multiplicom NV focussed on the development and commercialisation of DNA sequencing products and Biosurfit SA, focussed on development and commercialisation of point-of-care diagnostic products.

EpiStem Holdings Plc Announces Successful Completion of Genedrive(R) Indian Clinical Trials and Regulatory Submission

EpiStem Holdings Plc announced the successful completion of its Genedrive(R) Indian clinical evaluation study and the regulatory submission with the Drug Controller General of India (DCGI) of its first test for the diagnosis of Tuberculosis and Rifampicin antibiotic resistance (TB). Epistem is now awaiting approval from the Indian regulator for a license to import and sell its first major infectious disease assay for TB, which is anticipated early in 2015. The clinical evaluation study was completed over a 4-month period ending September 2014 and involved the testing of 300 randomly referred and blinded pulmonary 'raw sputa' TB patient samples, with each Genedrive(R) test taking approximately 1 hour to complete. The test results demonstrated high levels of sensitivity (93%) and specificity (94%), versus the industry gold standard 'culture test' method for TB. The study also measured those patients showing resistance to the first line antibiotic Rifampicin, a growing concern due to irregular and incomplete treatment with differing regimens giving rise to the growth in Multi Drug Resistance-TB (MDR-TB) cases in India. These levels of accuracy, speed to result and simplicity of operation compare favourably with other molecular and non-molecular TB test methods, such as culture which has lengthy turn around times to test result (culture testing typically takes up to 42 days to obtain a confirmed TB test result), microscopy which delivers less accurate results (lower sensitivity and specificity) and other competitive molecular tests which can require lengthy upfront extraction processes, extended timescales to test result and/or increased cost. Genedrive's advantage is its ability to deliver speed to result, high levels of molecular accuracy and simplicity of use at low cost in remote/non laboratory-based settings, making it suitable for tackling disease in low-income countries and developing nations. India is the high TB burden country in the world with World Health Organisation (WHO) statistics for 2011 giving an estimated incidence figure of 2.2 million cases of TB for India out of a global incidence of 8.7 million cases. Indian distributor partner Xcelris Lab is preparing for the launch of TB test including first line antibiotic resistance (Rifampicin) detection.

Epistem Holdings plc Reports Consolidated Earnings Results for the Year Ended June 30, 2014

EpiStem Holdings Plc reported consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue and other income of GBP 5,761,000 compared to GBP 5,356,000 for the same period a year ago. Operating loss was GBP 2,295,000 compared to GBP 1,519,000 a year ago. Loss on ordinary activities before taxation was GBP 2,349,000 compared to GBP 1,459,000 a year ago. Total Comprehensive loss for the year was GBP 1,693,000 compared to GBP 1,163,000 a year ago. Basic and diluted loss per share was 17.4 pence compared to 12.5 pence a year ago. Net cash outflow from operating activities was GBP 1,147,000 compared to GBP 612,000 a year ago. Acquisition of fixed assets was GBP 1,481,000 compared to GBP 1,727,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EHP:LN 277.50 GBp 0.00

EHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EHP.
View Industry Companies
 

Industry Analysis

EHP

Industry Average

Valuation EHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.3x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPISTEM HOLDINGS PLC, please visit www.epistem.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.